---
schema_version: "secwatch.filing_event.v1"
accession: "0001847903-23-000153"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T12:41:33.017388+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Centessa Q2 net loss $24.9M; cash $303.6M; SerpinPC registrational study dosing

## Summary
- Cash, equivalents and short-term investments $303.6M as of June 30; plus $15M ATM gross proceeds in Aug 2023; runway into 2026.
- Net loss $24.9M vs $64.7M YoY, including $24.1M tax benefit from valuation allowance release on deferred tax assets.
- R&D expenses $33.7M (Q2 2023) vs $53.7M (Q2 2022); G&A $13.3M vs $14.8M.
- SerpinPC registrational PRESent-2 study first subject dosed July 2023; FDA Fast Track designation received May 2023.
- LB206 (PD-L1xCD3 LockBody) nominated as second development candidate; ORX750 IND-enabling; preclinical data at World Sleep Congress Oct 2023.

## SEC filing metadata
- accession: 0001847903-23-000153
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000184790323000153/0001847903-23-000153-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000184790323000153/cnta-20230814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847903-23-000153
- JSON: https://secwatch.observer/filing/0001847903-23-000153.json
- Plain text: https://secwatch.observer/filing/0001847903-23-000153.txt

## Key facts
- Earnings Releases
  Centessa Pharmaceuticals plc reported for the second quarter ended June 30, 2023 results: net income $24.9 million.
  - Period: for the second quarter ended June 30, 2023
  - Net income: $24.9 million
  - Result: reported results
  source text: Centessa Pharmaceuticals plc (the "Company") announced its financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1847903/000184790323000153/0001847903-23-000153-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.